Ethinylestradiol 20mcg/drospirenone 3mg combined oral contraceptive administered in a 24/4 regimen in the treatment of premenstrual dysphoric disorder-related symptoms and functional impairment: a randomized, multicenter, double-blind, parallel study.

Trial Profile

Ethinylestradiol 20mcg/drospirenone 3mg combined oral contraceptive administered in a 24/4 regimen in the treatment of premenstrual dysphoric disorder-related symptoms and functional impairment: a randomized, multicenter, double-blind, parallel study.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2011

At a glance

  • Drugs Drospirenone/ethinylestradiol (Primary)
  • Indications Premenstrual dysphoric disorder
  • Focus Therapeutic Use
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top